George Freeman
Poquoson, VANPI 1194973867
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,993 of the $4,789 with a category attached, or 83.4%. 3 manufacturers reported payments, led by Merck at 53.0% of the total.
Across 55 payments — averaging $87.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Eli Lilly$2K
- Novo Nordisk$32
Across 4,437 payments — averaging $4854.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$6.1M
- Merck$4.2M
- Pfizer$3.2M
- Eli Lilly$1.9M
- AbbVie$936K
- Novavax Inc$922K
- plus $4.3M from 18 others
What the payments were for
- Travel & lodging$3,99383%
- Food & beverage$72715%
- Education$681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 26 | $2,538 |
| Eli Lilly | 28 | $2,219 |
| Novo Nordisk | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GARDASIL 9$737
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.